The FDA Just Sent Ocugen a Warning. Should Investors Care?

For biotech companies, it's never a good sign to have testy interactions with federal regulators. Ocugen (NASDAQ: OCGN) knows this all too well. The company's coronavirus vaccine candidate in development was placed on a clinical hold by the Food and Drug Administration (FDA) on April 12. A mere three days later, Ocugen earned another regulatory rebuke for its handling of data from a trial investigating a gene therapy for ocular diseases.

Should the more recent issue with regulators go unaddressed, there might be real financial consequences. Is this cause for shareholders to head for the hills, or is it a potential buying opportunity on the horizon? 

Image source: Getty Images.

Continue reading

Source Fool.com